DiaMedica Therapeutics, Inc.
DiaMedica-Logo
Navigate DiaMedica Therapeutics, Inc.
Home
About Us
Overview
Leadership Team
Board of Directors
Advisors
Pipeline
Pipeline
Lead Product
Chronic Kidney Disease
Acute Ischemic Stroke
Clinical Trials
News
Investors
Investor Overview
Events and Presentations
Nasdaq Stock Information
Analyst Coverage
Financials & Filings
Corporate Governance
FAQ
Email Alerts
Careers
Contact
Home
News
News
All News
By Year:
2019
2018
2017
2016
Dec 21, 2017
DiaMedica Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
Dec 18, 2017
DiaMedica Therapeutics Completes Non-Brokered Private Placement
Dec 13, 2017
DiaMedica Therapeutics Announces Non-Brokered Private Placement
Nov 22, 2017
DiaMedica Therapeutics Announces Ethics Committee Clearance at First Site to Initiate REMEDY Phase 2 Trial for Acute Ischemic Stroke
Nov 7, 2017
DiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials
Oct 31, 2017
DiaMedica Announces Dr. Robert Stanton as Scientific Advisor for Upcoming Chronic Kidney Disease Trials
Oct 27, 2017
DiaMedica Therapeutics Announces the Early Exercise of Warrants from Strategic Investor
Sep 11, 2017
DiaMedica Announces the Initiation of Phase 2 Trial Evaluating DM199 (Recombinant Human KLK1) in Patients with Acute Ischemic Stroke
May 1, 2017
DiaMedica Announces Recently Granted Formulation Patent in U.S. for DM199
Apr 25, 2017
DiaMedica Announces Dr. Nancy Chang to its Strategic Advisory Board
1
2
Next »